What is Pendulum Therapeutics?
Pendulum Therapeutics stands at the forefront of the microbiome industry, uniquely applying high-resolution, long-read DNA sequencing to create novel interventions. Their flagship product, Pendulum Glucose Control, is a clinically validated Medical Probiotic designed to aid in the dietary management of type 2 diabetes by positively influencing the gut microbiome to help manage A1C and blood sugar levels. Founded in 2012 by a multidisciplinary team of scientists, the company has built a proprietary innovation platform that facilitates the rapid translation of microbiome discoveries from initial research through rigorous human clinical validation. Formerly known as Whole Biome, Pendulum Therapeutics is headquartered in San Francisco.
How much funding has Pendulum Therapeutics raised?
Pendulum Therapeutics has raised a total of $117.5M across 4 funding rounds:
Series A
$18.5M
Series B
$35M
Series C
$54M
Other Financing Round
$10M
Series A (2017): $18.5M with participation from True Ventures, Khosla Ventures, and Morgan Noble
Series B (2019): $35M led by Sequoia Capital
Series C (2021): $54M supported by True Ventures, Meritech, Khosla Ventures, and Steamboat Ventures
Other Financing Round (2023): $10M featuring Fonterra
Key Investors in Pendulum Therapeutics
Fonterra
Fonterra, a global leader in dairy export and innovation, participated in Pendulum Therapeutics' latest financing round. The company's involvement may signal a strategic interest in the intersection of nutrition, the microbiome, and health management.
True Ventures
True Ventures, a prominent venture capital firm known for its early-stage investments in technology and AI, has been a consistent backer of Pendulum Therapeutics, providing crucial capital and guidance for the company's growth.
Khosla Ventures
Khosla Ventures, a venture capital firm focused on breakthrough technologies across various sectors including health and AI, has supported Pendulum Therapeutics, likely recognizing the disruptive potential of microbiome-based health solutions.
What's next for Pendulum Therapeutics?
With substantial enterprise-level funding and a recent strategic investment, Pendulum Therapeutics is well-positioned for accelerated growth and market expansion. The company's focus on translating scientific discovery into clinically validated products, particularly for chronic conditions like type 2 diabetes, suggests a strategic direction towards scaling its commercialization efforts and potentially exploring new therapeutic areas within the microbiome space. Continued investment will likely fuel further research and development, clinical trials, and the broader adoption of their innovative medical probiotics.
See full Pendulum Therapeutics company page
